Ivabradine Tablets and Zykadia
Determining the interaction of Ivabradine Tablets and Zykadia and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivabradine, which is primarily metabolized by the isoenzyme. According to the product labeling, administration of ivabradine with the potent CYP450 3A4 inhibitor ketoconazole (200 mg once daily) resulted in approximately 3.5- and 7-fold increases in ivabradine peak plasma concentration (Cmax) and systemic exposure (AUC), respectively, compared to administration of ivabradine alone. Elevated plasma levels of ivabradine may increase the risk of excessive bradycardia and conduction disturbances. MANAGEMENT: Concomitant use of ivabradine with potent CYP450 3A4 inhibitors is considered contraindicated. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Corlanor (ivabradine)." Amgen USA, Thousand Oaks, CA.
Professional:CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivabradine, which is primarily metabolized by the isoenzyme. According to the product labeling, administration of ivabradine with the potent CYP450 3A4 inhibitor ketoconazole (200 mg once daily) resulted in approximately 3.5- and 7-fold increases in ivabradine peak plasma concentration (Cmax) and systemic exposure (AUC), respectively, compared to administration of ivabradine alone. Elevated plasma levels of ivabradine may increase the risk of excessive bradycardia and conduction disturbances.
MANAGEMENT: Concomitant use of ivabradine with potent CYP450 3A4 inhibitors is considered contraindicated.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Corlanor (ivabradine)." Amgen USA, Thousand Oaks, CA.
Generic Name: ivabradine
Brand name: Corlanor
Synonyms: Ivabradine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ivabradine Tablets-Zylet
- Ivabradine Tablets-Zylet ophthalmic
- Ivabradine Tablets-Zyloprim
- Ivabradine Tablets-Zymine Liquid
- Ivabradine Tablets-Zymine-D
- Ivabradine Tablets-Zyncof
- Zykadia-Ivacaftor
- Zykadia-Ivacaftor and lumacaftor
- Zykadia-Ivacaftor and tezacaftor
- Zykadia-Ivacaftor Granules
- Zykadia-Ivacaftor Tablets
- Zykadia-Ivermectin